Table 2.
Parameter | I—non-PAH control | II—early PAH | III—end-stage PAH | IV—end-stage PAH with myocarditis | p-value ANOVA or Kruskal–Wallis test |
Pairwise comparisons | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
p-value I vs. II |
p-value I vs. III |
p-value I vs. IV |
p-value II vs. III |
p-value II vs. IV |
p-value III vs. IV |
||||||
LVFWTd (mm) | 0.20 ± 0.04 | 0.21 ± 0.03 | 0.19 ± 0.05 | 0.21 ± 0.03 | 0.569 | ns | ns | ns | ns | ns | ns |
RVFWTd (mm) | 0.61 ± 0.05 | 0.78 ± 0.04 | 0.95 ± 0.20 | 0.88 ± 0.33 | <0.001 | <0.001 | <0.001 | 0.002 | 0.007 | 0.305 | 1.000 |
TAPSE (mm) | 1.11 ± 0.64 | 1.02 ± 0.13 | 0.72 ± 0.16 | 0.71 ± 0.14 | <0.001 | 1.000 | 0.010 | 0.129 | <0.001 | <0.001 | 1.000 |
PAAT/CL (mm/s) | 0.23 ± 0.15 | 0.21 ± 0.05 | 0.14 ± 0.06 | 0.12 ± 0.04 | <0.001 | 1.000 | 0.007 | 0.017 | 0.127 | 0.086 | 1.000 |
LV systolic pressure (mmHg) | 90.09 ± 15.90 | 80.50 ± 3.00 | 46.94 ± 14.65 | 43.00 ± 9.56 | <0.001 | 1.000 | <0.001 | 0.004 | 0.012 | 0.040 | 1.000 |
LV diastolic pressure (mmHg) | 9.00 ± 4.86 | 7.50 ± 2.08 | 6.94 ± 4.02 | 3.50 ± 1.91 | 0.073 | ns | ns | ns | ns | ns | ns |
RV systolic pressure (mmHg) | 20.20 ± 6.60 | 28.50 ± 5.20 | 45.10 ± 12.83 | 49.67 ± 19.91 | <0.001 | <0.001 | <0.001 | 0.006 | 0.001 | 0.011 | 1.000 |
RV diastolic pressure (mmHg) | 4.40 ± 2.55 | 8.00 ± 2.00 | 6.00 ± 3.89 | 6.67 ± 4.68 | 0.012 | 0.008 | 0.748 | 1.000 | 0.161 | 0.508 | 1.000 |
LV: left ventricle; LVFWTd: end-diastolic left ventricular free wall thickness; PAAT/CL: pulmonary artery acceleration time normalized to cycle length; PAH: pulmonary arterial hypertension; RV: right ventricle; RVFWTd: end-diastolic right ventricular free wall thickness; TAPSE: tricuspid annular plane systolic excursion
Statistically significant p-values are given in italics